Related Experiment Video

Updated: Jun 6, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Pathway of LCK Tyrosine Kinase and mTOR Signaling in Children with T-Cell Acute Lymphoblastic Leukemia

Agata Rocka1, Maria Suchcicka2, Aleksandra M Jankowska2

  • 1Pediatric Radiology, Medical University of Lublin, Medical University of Lublin, Prof. Antoni Gębali 6, Lublin, 20-093, Poland.

The Application of Clinical Genetics
|November 25, 2024
PubMed

Insights

Targeting LCK tyrosine kinase and mTOR signaling pathways shows promise for treating T-cell acute lymphoblastic leukemia (T-ALL). Further research in pediatric T-ALL is crucial for optimizing drug development and understanding therapeutic implications.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • T-cell acute lymphoblastic leukemia (T-ALL) is a significant hematologic malignancy.
  • Signaling pathways, including LCK tyrosine kinase and mTOR, are implicated in T-ALL pathogenesis.
  • Pediatric T-ALL presents unique challenges requiring targeted therapeutic strategies.

Purpose of the Study:

  • To review and analyze current research on targeting LCK and mTOR signaling pathways in T-ALL drug development.
  • To focus on the role of these pathways in pediatric T-ALL.
  • To identify potential therapeutic targets for novel drug discovery.

Main Methods:

  • Systematic literature review of existing research.
  • Analysis of studies focusing on LCK tyrosine kinase and mTOR signaling.
  • Examination of data related to pediatric T-ALL patient populations.

Main Results:

  • LCK tyrosine kinase and mTOR signaling pathways are critical regulators of T-cell cycle progression.
  • These pathways represent promising targets for therapeutic intervention in T-ALL.
  • Current literature indicates a significant role in T-cell regulation, suggesting potential for drug development.

Conclusions:

  • LCK and mTOR signaling pathways significantly influence T-cell cycle regulation in T-ALL.
  • Further investigation, especially in pediatric T-ALL, is essential for optimizing drug development.
  • Continued research is vital to fully elucidate the therapeutic potential of targeting these pathways.
Keywords:
T-ALLpediatricsignaling pathwaystargeted therapy

More Related Videos

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.3K
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K